BACKGROUND: Thymic epithelial tumors (TETs) are rare thoracic malignancies, commonly divided into two different histopathological entities, thymoma (T) and thymic carcinoma (TC). To date, there are no specific biomarkers for monitoring the biological course of these rare tumors. We carried out a single center study aiming at the detection of circulating cell-free DNA (ccfDNA) and the correlation of its levels with metastatic dissemination and histological subtype in patients with TETs. METHODS: From July 2018 to January 2020, 5-ml blood samples from 26 patients with advanced TET (aTET) (11 patients with TC and 15 patients with T) and from six patients with completely resected TET (cr-TET), were prospectively obtained before the initiation of systemic therapy. Blood samples from 10 healthy donors were used as control. The QIAamp MinElute ccfDNA Kits was used for ccfDNA isolation from plasma; real-time PCR was used for cfDNA quantification. RESULTS: We found significantly higher ccfDNA amount in patients with T and TC compared to controls, with median ccfDNA level of 3.3 ng/µl, 11.4 ng/µl and 25.6 ng/µl, for healthy donors, T and TC patients, respectively (p<0.001). No significant difference was found between cr-TET and controls (p = 0.175). ccfDNA concentrations were higher in metastatic (M1a and M1b) compared to non-metastatic (M0) TETs (25.6 ng/µl versus 7.2 ng/µl; p= 0.037). No significant correlation was found either between ccfDNA and disease stage, according to both the Masaoka-Koga (p= 0.854) and the TNM 8th edition staging systems (p = 0.66), or between ccfDNA levels and overall tumor burden, estimated according RECIST 1.1 criteria (r = 0.07, p = 0.725). CONCLUSIONS: To the best of our knowledge, this is the first study that prospectively explores detection and quantification of ccfDNA in TETs. Higher baseline cfDNA levels have been observed in both advanced T and TC comparing to the control group.
BACKGROUND: Thymic epithelial tumors (TETs) are rare thoracic malignancies, commonly divided into two different histopathological entities, thymoma (T) and thymic carcinoma (TC). To date, there are no specific biomarkers for monitoring the biological course of these rare tumors. We carried out a single center study aiming at the detection of circulating cell-free DNA (ccfDNA) and the correlation of its levels with metastatic dissemination and histological subtype in patients with TETs. METHODS: From July 2018 to January 2020, 5-ml blood samples from 26 patients with advanced TET (aTET) (11 patients with TC and 15 patients with T) and from six patients with completely resected TET (cr-TET), were prospectively obtained before the initiation of systemic therapy. Blood samples from 10 healthy donors were used as control. The QIAamp MinElute ccfDNA Kits was used for ccfDNA isolation from plasma; real-time PCR was used for cfDNA quantification. RESULTS: We found significantly higher ccfDNA amount in patients with T and TC compared to controls, with median ccfDNA level of 3.3 ng/µl, 11.4 ng/µl and 25.6 ng/µl, for healthy donors, T and TC patients, respectively (p<0.001). No significant difference was found between cr-TET and controls (p = 0.175). ccfDNA concentrations were higher in metastatic (M1a and M1b) compared to non-metastatic (M0) TETs (25.6 ng/µl versus 7.2 ng/µl; p= 0.037). No significant correlation was found either between ccfDNA and disease stage, according to both the Masaoka-Koga (p= 0.854) and the TNM 8th edition staging systems (p = 0.66), or between ccfDNA levels and overall tumor burden, estimated according RECIST 1.1 criteria (r = 0.07, p = 0.725). CONCLUSIONS: To the best of our knowledge, this is the first study that prospectively explores detection and quantification of ccfDNA in TETs. Higher baseline cfDNA levels have been observed in both advanced T and TC comparing to the control group.
Authors: Andrew G Nicholson; Frank C Detterbeck; Mirella Marino; Jhingook Kim; Kelly Stratton; Dorothy Giroux; Hisao Asamura; John Crowley; Conrad Falkson; Pier Luigi Filosso; Giuseppe Giaccone; James Huang; Kazuya Kondo; Marco Lucchi; Edith M Marom; Meinoshin Okumura; Enrico Ruffini; Paul Van Schil Journal: J Thorac Oncol Date: 2014-09 Impact factor: 15.609
Authors: Hae Su Kim; Ji Yun Lee; Sung Hee Lim; Jong-Mu Sun; Se Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn Journal: Lung Cancer Date: 2016-03-26 Impact factor: 5.705
Authors: Nicholas C Eastley; Barbara Ottolini; Rita Neumann; Jin-Li Luo; Robert K Hastings; Imran Khan; David A Moore; Claire P Esler; Jacqueline A Shaw; Nicola J Royle; Robert U Ashford Journal: Oncotarget Date: 2018-01-19
Authors: César Serrano; Ana Vivancos; Antonio López-Pousa; Judit Matito; Francesco M Mancuso; Claudia Valverde; Sergi Quiroga; Stefania Landolfi; Sandra Castro; Cristina Dopazo; Ana Sebio; Anna C Virgili; María M Menso; Javier Martín-Broto; Miriam Sansó; Alfonso García-Valverde; Jordi Rosell; Jonathan A Fletcher; Suzanne George; Joan Carles; Joaquín Arribas Journal: BMC Cancer Date: 2020-02-05 Impact factor: 4.430
Authors: Martina Imbimbo; Margaret Ottaviano; Milena Vitali; Alessandra Fabbri; Giovanni Leuzzi; Michele Fiore; Davide Franceschini; Giulia Pasello; Matteo Perrino; Marco Schiavon; Giancarlo Pruneri; Angelo Paolo Dei Tos; Claudia Sangalli; Marina Chiara Garassino; Rossana Berardi; Alessandra Alessi; Giuseppina Calareso; Iacopo Petrini; Marta Scorsetti; Vieri Scotti; Lorenzo Rosso; Federico Rea; Ugo Pastorino; Paolo Giovanni Casali; Sara Ramella; Umberto Ricardi; Laura Abate-Daga; Valter Torri; Annalisa Trama; Giovannella Palmieri; Mirella Marino; Paolo Andrea Zucali Journal: Cancer Treat Rev Date: 2018-10-05 Impact factor: 12.111